Y-mAbs

$35.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.49 (+4.42%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Y-mAbs and other stocks, options, and ETFs commission-free!

About YMAB

Y-mAbs Therapeutics, Inc. Common Stock, also called Y-mAbs, is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY. The listed name for YMAB is Y-mAbs Therapeutics, Inc. Common Stock.

CEO
Claus Juan Møller-San Pedro
Employees
65
Headquarters
New York, New York
Founded
2015
Market Cap
1.71B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
433.22K
High Today
$35.69
Low Today
$33.43
Open Price
$33.60
Volume
438.90K
52 Week High
$55.22
52 Week Low
$14.16

YMAB Earnings

-$1.01
-$0.83
-$0.66
-$0.48
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.51 per share
Actual
-$0.48 per share
Replay Earnings Call

You May Also Like

VPV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure